A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Background: This phase 2 study evaluated trebananib (AMG 386), an investigational peptide-Fc fusion protein that neutralises the interaction between angiopoietins-1/2 and the Tie2 receptor, plus FOLFIRI as second-line treatment for patients with metastatic colorectal cancer. Methods: Patients had ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2013-02, Vol.108 (3), p.503-511
Hauptverfasser:	Peeters, M, Strickland, A H, Lichinitser, M, Suresh, A V S, Manikhas, G, Shapiro, J, Rogowski, W, Huang, X, Wu, B, Warner, D, Jain, R, Tebbutt, N C
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/436/108 692/699/67/1059 692/699/67/1504/1885 Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Adult Aged Angiogenesis Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - analysis Biomedical and Life Sciences Biomedicine Camptothecin - administration & dosage Cancer Research Cancer therapies Chemotherapy Clinical Study Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Double-Blind Method Drug Resistance Epidemiology Female Fluorouracil - administration & dosage Humans International Agencies Leucovorin - administration & dosage Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - secondary Male Metastasis Middle Aged Molecular Medicine Oncology Peptides Prognosis Recombinant Fusion Proteins - administration & dosage Salvage Therapy Survival Rate Vascular endothelial growth factor Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!